Related Experiment Videos
Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System
Amnon C Sintov1,2, Haim V Levy3, Igor Greenberg4
1Department of Biomedical Engineering, Faculty of Engineering Sciences, Ben-Gurion University of the Negev, P.O. Box 653, Be'er Sheva, 84105, Israel. asintov@bgu.ac.il.
Pharmaceutical Research
|April 14, 2017
Summary
This study introduces a novel nano-micellar system for transdermal levodopa (L-DOPA) delivery, improving skin permeation and absorption. This approach offers a potential new treatment for Parkinson's disease, reducing motor fluctuations.
Area of Science:
- Pharmacology
- Drug Delivery Systems
- Neuroscience
Background:
- Oral levodopa (L-DOPA) administration for Parkinson's disease leads to rapid elimination and blood level fluctuations.
- These fluctuations are linked to motor complications and dyskinesias, posing treatment challenges.
- Transdermal drug delivery offers continuous and controlled systemic therapeutic levels.
Purpose of the Study:
- To investigate the transdermal delivery of levodopa (L-DOPA) using an innovative self-assembling nano-micellar system (SANS).
- To overcome challenges of L-DOPA's poor solubility and limited skin permeability for effective transdermal delivery.
- To achieve continuous dopaminergic stimulation (CDS) and reduce motor fluctuations in Parkinson's disease.
Main Methods:
- Development of a self-assembling nano-micellar system (SANS) loaded with 2% L-DOPA and 1% carbidopa.
- In vitro testing of the SANS formulation for transdermal delivery.
- In vivo pharmacokinetic studies using a multiple-dose regimen in rabbits.
Main Results:
- Demonstrated significantly increased percutaneous permeation of L-DOPA.
- Showcased enhanced systemic absorption of L-DOPA.
- Validated the efficacy of the SANS for transdermal L-DOPA delivery in preclinical studies.
Conclusions:
- The developed SANS facilitates effective transdermal delivery of L-DOPA.
- Therapeutic effectiveness may be achieved with once-daily or twice-daily dosing regimens.
- This approach holds promise for managing Parkinson's disease symptoms and improving patient compliance.